[Form 4] Tourmaline Bio, Inc. Insider Trading Activity
Rhea-AI Filing Summary
Tourmaline Bio (TRML) reported an insider transaction tied to its merger with Novartis AG. On October 28, 2025, a cash tender offer was completed in which each Tourmaline common share was exchanged for $48.00 in cash per share, as disclosed.
The filing reflects the Chief Regulatory Officer’s equity being settled under the merger terms. Restricted shares vested immediately prior to the effective time and were treated as common shares for the cash consideration. Outstanding, unexercised employee stock options were automatically canceled and converted into a cash right equal to the $48.00 consideration minus the option’s exercise price, multiplied by the number of underlying shares.
Positive
- None.
Negative
- None.
Insights
Insider Form 4 confirms $48/share tender mechanics and option cash-out.
The transaction records the completion of a cash tender offer at $48.00 per share tied to the Novartis acquisition. For equity awards, the document states that restricted shares vested immediately prior to the effective time and were treated as common shares for purposes of receiving cash consideration.
Employee stock options were canceled and converted into a cash right equal to the spread between $48.00 and the respective exercise price, multiplied by the options’ share count. This is standard treatment in cash mergers and aligns holder outcomes with the deal price.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Employee Stock Option (Right to Buy) | 96,146 | $0.00 | -- |
| Disposition | Employee Stock Option (Right to Buy) | 46,774 | $0.00 | -- |
| Disposition | Employee Stock Option (Right to Buy) | 58,000 | $0.00 | -- |
| U | Common Stock | 40,538 | $0.00 | -- |
| Disposition | Common Stock | 11,046 | $0.00 | -- |
Footnotes (1)
- This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share. Pursuant to the terms of the Merger Agreement, each restricted Share outstanding and subject to the Issuer's repurchase right as of immediately prior to the Effective Time became fully vested effective as of immediately prior to the Effective Time, and, by virtue of the merger and net of any applicable withholding taxes, was treated as a Share for all purposes under the terms of the Merger Agreement. Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.
